Venetoclax, Azacitidine Combined With Homoharringtonine Versus Venetoclax and Azacitidine in Newly Diagnosed Elderly (60-75 Years) Acute Myeloid Leukemia: A Multicenter, Open-label, Randomized, Controlled Clinical Trial is a PHASE3 clinical asset sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine in Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years). SEO and diligence focus: Venetoclax, Azacitidine, Homoharringtonine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.